| ObjectiveObserve the possible effect of mesenchymal stem cells transplantation on collageninduced arthritis(CIA), by detecting the expression of TNF-αã€IL-6ã€IL-17ã€RANKLã€OPGã€MCP-1ã€RANTESã€IP-10ã€VEGF in serum, investigate the immunomodulatory mechanism of BMSCs.Methods1. The differentiation of ability to identify Bone marrow mesenchymal stem cells.When cell fusion was to 80% and passaged at a rate of 1 to 3 for expansion. Flow cytometry detects BMSCs’ surface antigen CD44ã€CD105ã€CD29ã€CD34ã€CD45 and CD31 expression,through the exclusion of the cultured cells for identification of BMSCs.Mesenchymal stem cells induced to differentiate into bone cells and adipocytes.2. Grouping A total of six groups. The treatment groups contain the early and advanced stages, Meanwhile, there are normal control and model control. The latter also contains the early and advanced stages.Also,there is the positive control group of MTX.3. BMSCs transplantion the cell population of transplantation. The 1×107/kg cells by tail vein injection.4. Index detection Take blood, separate and obtain serum, observe the expression of TNF-αã€IL-6ã€IL-17ã€RANKLã€OPGã€MCP-1ã€RANTESã€IP-10ã€VEGF by Aimplex and FCAP Array software(V3.0) derived data, and collect data for statistical analysis.Results1. Cells were positive for CD44ã€CD105 and CD29, but negative for CD45ã€CD34ã€CD31. Ability of mesenchymal stem cells induced to differentiate into osteoblasts and adipocytes.2.The level of TNF-αã€IL-6ã€RANKLã€VEGFã€RANTESã€MCP-1ã€IP-10 was higher in CIA control group than normal group,P<0.05;But IL-17 A 〠OPG showed no statistically significant difference(P>0.05).3. Compared to the CIA control group the level of TNF-αã€IL-6ã€RANTESã€MCP-1ã€IP-10ã€RANKL was decreased markedly in the MTX treatment groups( P<0.05). But VEGF showed no statistically significant difference(P>0.05).4. The level of TNF-αand IL-6 were lower in early and late treatment groups than CIA control groups(P<0.05). While the early MSCs treatment group versus the MTX treatment group the level of TNF-αand IL-6 showed no statistically significant difference(P>0.05). But the late MSCs treatment group versus the MTX treatment group showed statistically significant difference(P>0.05).5. The level of RANTES and IP-10 were lower in early treatment groups than CIA control groups(P<0.05),in the late treatment groups showed no statistically significant difference(P>0.05). Compared to the late treatment group the level of RANTESã€IP-10 was decreased markedly in the early treatment groups( P<0.05). While the early and late MSCs treatment group versus the MTX treatment group showed no statistically significant difference(P>0.05).6. The level of MCP-1 were lower in early treatment groups than CIA control groups(P<0.05),in the late treatment groups showed no statistically significant difference(P>0.05). Compared to the late treatment group the level of MCP-1was decreased markedly in the early treatment groups( P<0.05). While the early MSCs treatment group versus the MTX treatment group the level of MCP-1 showed no statistically significant difference(P>0.05). But the late MSCs treatment group versus the MTX treatment group showed statistically significant difference(P>0.05).ConclusionsIn CIA rats have immune function disorders.The mesenchymal stem cellstransplantation in CIA rats has remarkableffect in inhibiting serum TNF-α 〠IL-6 ã€RANTESã€MCP-1ã€IP-10.Mesenchymal stem cell transplantation in CIA rats the early treatment effects is better than late. It indicated that the mesenchymal stem cells transplantation in CIA rats has the function in immunomodulation. |